<DOC>
	<DOCNO>NCT02766777</DOCNO>
	<brief_summary>A study safety Lubiprostone pediatric subject age ≥ 6 Years &lt; 18 year diagnose Functional Constipation</brief_summary>
	<brief_title>Evaluation Safety Lubiprostone Pediatric Subjects Aged ≥ 6 Years &lt; 18 Years With Functional Constipation</brief_title>
	<detailed_description>To assess long-term safety tolerability oral lubiprostone 12 24mcg capsule dose twice daily ( BID ) administer orally 24 week pediatric subject functional constipation . Evaluation lubiprostone safety tolerability primary objective study .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Lubiprostone</mesh_term>
	<criteria>Medicallyconfirmed diagnosis Functional Constipation per Rome III Diagnostic Criteria Childhood Functional Constipation At least 6 year age less 18 year age time randomisation Only stable dose selective serotonin reuptake inhibitor ( SSRIs ) , serotoninspecific reuptake inhibitor ( SNRIs ) , monoamine oxidase inhibitor ( MAO ) inhibitor allow subject take antidepressant Any gastrointestinal ( GI ) condition , constipation , affect GI motility defecation Untreated faecal impaction time screen Medical/surgical condition might interfere absorption , distribution , metabolism , excretion study medication</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>